VERTEX PHARMACEUTICALS INC / MA OCI, before Reclassifications, Net of Tax, Attributable to Parent
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported OCI, before Reclassifications, Net of Tax, Attributable to Parent of $36.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2026-06-30 was $13.30M.
- VERTEX PHARMACEUTICALS INC / MA oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2026-03-31 was $22.70M.
- VERTEX PHARMACEUTICALS INC / MA oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-12-31 was $21.70M, a 81.69% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-09-30 was $9.30M, a 66.07% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA oci, before reclassifications, net of tax, attributable to parent for fiscal 2025 was -$193.30M, a 215.06% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA oci, before reclassifications, net of tax, attributable to parent for fiscal 2024 was $168.00M, a 1853.49% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA oci, before reclassifications, net of tax, attributable to parent for fiscal 2023 was $8.60M, a 93.08% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA oci, before reclassifications, net of tax, attributable to parent for fiscal 2022 was $124.20M, a 103.94% increase from fiscal 2021.
| Period end | OCI, before Reclassifications, Net of Tax, Attributable to Parent 3 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 3 month as first filed | OCI, before Reclassifications, Net of Tax, Attributable to Parent 6 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 6 month as first filed | OCI, before Reclassifications, Net of Tax, Attributable to Parent 9 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 9 month as first filed | OCI, before Reclassifications, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $13.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $36.00M 10-Q · filed 2026-08-04 | $57.70M derived: sum of 3 quarters · filed 2026-08-04 | $67.00M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $22.70M 10-Q · filed 2026-05-05 | $44.40M derived: sum of 2 quarters · filed 2026-05-05 | $53.70M derived: sum of 3 quarters · filed 2026-05-05 | -$131.50M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $21.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $31.00M derived: sum of 2 quarters · filed 2026-02-13 | -$154.20M derived: sum of 3 quarters · filed 2026-08-04 | -$193.30M 10-K · filed 2026-02-13 | |||
| 2025-09-30 | $9.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$175.90M derived: sum of 2 quarters · filed 2026-08-04 | -$215.00M 10-Q · filed 2025-11-04 | -$96.50M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | -$185.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$224.30M 10-Q · filed 2026-08-04 | -$105.80M derived: sum of 3 quarters · filed 2026-08-04 | -$100.20M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | -$39.10M 10-Q · filed 2026-05-05 | $79.40M derived: sum of 2 quarters · filed 2026-05-05 | $85.00M derived: sum of 3 quarters · filed 2026-05-05 | $95.40M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $118.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $124.10M derived: sum of 2 quarters · filed 2026-02-13 | $134.50M derived: sum of 3 quarters · filed 2026-02-13 | $168.00M 10-K · filed 2026-02-13 | |||
| 2024-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $16.00M derived: sum of 2 quarters · filed 2025-11-04 | $49.50M 10-Q · filed 2025-11-04 | $36.00M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-06-30 | $10.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $43.90M 10-Q · filed 2025-08-05 | $30.40M derived: sum of 3 quarters · filed 2026-02-13 | $69.40M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-03-31 | $33.50M 10-Q · filed 2025-05-06 | $20.00M derived: sum of 2 quarters · filed 2026-02-13 | $59.00M derived: sum of 3 quarters · filed 2026-02-13 | $38.80M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2023-12-31 | -$13.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $25.50M derived: sum of 2 quarters · filed 2026-02-13 | $5.30M derived: sum of 3 quarters · filed 2026-02-13 | $8.60M 10-K · filed 2026-02-13 | |||
| 2023-09-30 | $39.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $18.80M derived: sum of 2 quarters · filed 2024-11-05 | $22.10M 10-Q · filed 2024-11-05 | -$37.50M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-06-30 | -$20.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$16.90M 10-Q · filed 2024-08-02 | -$76.50M derived: sum of 3 quarters · filed 2025-02-13 | $14.70M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-03-31 | $3.30M 10-Q · filed 2024-05-07 | -$56.30M derived: sum of 2 quarters · filed 2025-02-13 | $34.90M derived: sum of 3 quarters · filed 2025-02-13 | $116.30M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2022-12-31 | -$59.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $31.60M derived: sum of 2 quarters · filed 2025-02-13 | $113.00M derived: sum of 3 quarters · filed 2025-02-13 | $124.20M 10-K · filed 2025-02-13 | |||
| 2022-09-30 | $91.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $172.60M derived: sum of 2 quarters · filed 2023-11-07 | $183.80M 10-Q · filed 2023-11-07 | $195.50M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-06-30 | $81.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $92.60M 10-Q · filed 2023-08-02 | $104.30M derived: sum of 3 quarters · filed 2024-02-15 | $136.90M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-03-31 | $11.20M 10-Q · filed 2023-05-02 | $22.90M derived: sum of 2 quarters · filed 2024-02-15 | $55.50M derived: sum of 3 quarters · filed 2024-02-15 | $49.90M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2021-12-31 | $11.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $44.30M derived: sum of 2 quarters · filed 2024-02-15 | $38.70M derived: sum of 3 quarters · filed 2024-02-15 | $60.90M 10-K · filed 2024-02-15 | |||
| 2021-09-30 | $32.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $27.00M derived: sum of 2 quarters · filed 2022-10-28 | $49.20M 10-Q · filed 2022-10-28 | $49.18M 10-Q · filed 2021-11-03 | $12.51M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-06-30 | -$5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $16.60M 10-Q · filed 2022-08-05 | $16.58M 10-Q · filed 2021-07-30 | -$20.09M derived: sum of 3 quarters · filed 2023-02-10 | -$52.63M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-03-31 | $22.20M 10-Q · filed 2022-05-06 | $22.23M 10-Q · filed 2021-04-30 | -$14.49M derived: sum of 2 quarters · filed 2023-02-10 | -$47.03M derived: sum of 3 quarters · filed 2023-02-10 | -$69.55M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2020-12-31 | -$36.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | -$69.23M derived: sum of 2 quarters · filed 2023-02-10 | -$91.75M derived: sum of 3 quarters · filed 2023-02-10 | -$69.40M 10-K · filed 2023-02-10 | |||
| 2020-09-30 | -$32.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$55.06M derived: sum of 2 quarters · filed 2021-11-03 | -$32.71M 10-Q · filed 2021-11-03 | -$47.95M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-06-30 | -$22.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | -$171.00K 10-Q · filed 2021-07-30 | -$15.41M derived: sum of 3 quarters · filed 2022-02-09 | $14.70M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-03-31 | $22.35M 10-Q · filed 2021-04-30 | $7.11M derived: sum of 2 quarters · filed 2022-02-09 | $37.22M derived: sum of 3 quarters · filed 2022-02-09 | $34.46M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2019-12-31 | -$15.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $14.87M derived: sum of 2 quarters · filed 2022-02-09 | $12.11M derived: sum of 3 quarters · filed 2022-02-09 | $22.80M 10-K · filed 2022-02-09 | |||
| 2019-09-30 | $30.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $27.35M derived: sum of 2 quarters · filed 2020-10-30 | $38.04M 10-Q · filed 2020-10-30 | ||||
| 2019-06-30 | -$2.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $7.93M 10-Q · filed 2020-07-31 | |||||
| 2019-03-31 | $10.69M 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |